Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business

Stay Pausing Investments

Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business

Stay Pausing Investments
Revenue(RF), mln.USD
14
Assets(RF), mln.USD
16
Capital(RF), mln.USD
4
Staff(RF), 2021
56
Taxes(RF), mln.USD
1
The Company Statement
March 24, 2022

Received revenues in Russia in 2021. While remain committed to facilitating patient access to life-saving medicines in Russia, all non-essential business operations in the country have been suspended. Any profits made from the sale of medicines will be donated to the humanitarian efforts for Ukraine. The initiation of new clinical trial sites in Russia and Ukraine has been paused.

All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner